La Lettre du CancérologueLa Lettre du Cancérologue

Trastuzumab par voie sous-cutanée : résultats en néo-adjuvant

ESMO 2012 – D’après Melichar B, abstr. 254PD actualisé

Trastuzumab i.v.(n = 298)

Trastuzumab s.c.(n = 297)

Patients with ≥ 1 adverse event (any grade) 280 (93,9 %) 289 (97,3 %)

Patients with ≥ 1 severe event (grade 3-5) 155 (52,0 %) 154 (51,9 %)

Patients with ≥ 1 serious adverse event 37 (12,4 %) 62 (20,9 %)

Patients with adverse event leading to death 1 (< 1,0 %) 3 (1,0 %)

• The serious adverse event difference was partly attributable to infections ; the remaining serious adverse events were spread across various

categories and 25 events were not easily explicable by the route of delivery or mechanism of action

Tolérance observée dans l'étude HannaH